Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
β-1,4-Gal-T1 Double Nickase Plasmid (h): sc-403299-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- β-1,4-Gal-T1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- β-1,4-Gal-T1 Double Nickase Plasmid (h) and β-1,4-Gal-T1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting B4GALT1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: β-1,4-Gal-T1 Antibody (A-3): sc-515551
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
β-1,4-Gal-T1 Double Nickase Plasmid (h) | sc-403299-NIC | 20 µg | $410.00 | |||
β-1,4-Gal-T1 Double Nickase Plasmid (h2) | sc-403299-NIC-2 | 20 µg | $410.00 |
B4GALT1 encodes human β-1,4-Gal-T1, a Golgi-resident glycosyltransferase that transfers galactose to N-acetylglucosamine to generate Galβ1-4GlcNAc (LacNAc) structures on N- and O-linked glycans and glycolipids. This activity supports glycan maturation within the secretory pathway and shapes cell-surface glycosylation patterns that influence protein folding, trafficking, receptor signaling, and cell–cell or cell–matrix interactions. β-1,4-Gal-T1 function intersects with glycosylation-dependent processes such as lectin binding, immune recognition, and extracellular matrix remodeling. Altered B4GALT1 activity and LacNAc abundance have been associated with dysregulated glycoprotein function observed across diverse disease-relevant contexts, including congenital glycosylation disorders and malignancy-associated glycome changes.
β-1,4-Gal-T1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the B4GALT1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within B4GALT1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt B4GALT1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of B4GALT1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.